EP2173326A2 - Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation - Google Patents
Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisationInfo
- Publication number
- EP2173326A2 EP2173326A2 EP08806120A EP08806120A EP2173326A2 EP 2173326 A2 EP2173326 A2 EP 2173326A2 EP 08806120 A EP08806120 A EP 08806120A EP 08806120 A EP08806120 A EP 08806120A EP 2173326 A2 EP2173326 A2 EP 2173326A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- composition
- calcitriol
- phase
- oily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 229960005084 calcitriol Drugs 0.000 title claims abstract description 43
- 235000020964 calcitriol Nutrition 0.000 title claims abstract description 43
- 239000011612 calcitriol Substances 0.000 title claims abstract description 43
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 18
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 150000002632 lipids Chemical class 0.000 claims description 34
- 239000004094 surface-active agent Substances 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 25
- 239000003349 gelling agent Substances 0.000 claims description 20
- 239000003981 vehicle Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- 239000000787 lecithin Substances 0.000 claims description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 9
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000001879 gelation Methods 0.000 claims description 5
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical group 0.000 claims description 4
- 238000005063 solubilization Methods 0.000 claims description 4
- 230000007928 solubilization Effects 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 239000004064 cosurfactant Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 abstract description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 4
- 235000019166 vitamin D Nutrition 0.000 abstract description 4
- 239000011710 vitamin D Substances 0.000 abstract description 4
- 229940046008 vitamin d Drugs 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 58
- 239000003995 emulsifying agent Substances 0.000 description 19
- 238000000265 homogenisation Methods 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 17
- -1 calcitriol lipid Chemical class 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000007908 nanoemulsion Substances 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002088 nanocapsule Substances 0.000 description 4
- 239000012875 nonionic emulsifier Substances 0.000 description 4
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical class CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 2
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241001440269 Cutina Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 2
- 229940031674 laureth-7 Drugs 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940119519 peg-32 stearate Drugs 0.000 description 2
- 229940119517 peg-6 stearate Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- AMTPDECUCREDJD-UHFFFAOYSA-N (3-amino-2-methylpropanoyl) benzoate Chemical compound NCC(C)C(=O)OC(=O)C1=CC=CC=C1 AMTPDECUCREDJD-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- SOJKBVIEJXRQQT-UHFFFAOYSA-N 11-hexyloctacosan-11-ol Chemical compound CCCCCCCCCCCCCCCCCC(O)(CCCCCC)CCCCCCCCCC SOJKBVIEJXRQQT-UHFFFAOYSA-N 0.000 description 1
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- PSQFOYNNWBCJMY-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCOCCOCCO PSQFOYNNWBCJMY-UHFFFAOYSA-N 0.000 description 1
- XMVBHZBLHNOQON-UHFFFAOYSA-N 2-butyl-1-octanol Chemical compound CCCCCCC(CO)CCCC XMVBHZBLHNOQON-UHFFFAOYSA-N 0.000 description 1
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 1
- DEMBLPGWNXUBIQ-UHFFFAOYSA-N 2-dodecylhexadecan-1-ol Chemical compound CCCCCCCCCCCCCCC(CO)CCCCCCCCCCCC DEMBLPGWNXUBIQ-UHFFFAOYSA-N 0.000 description 1
- JQJGGMZIMBGQQY-UHFFFAOYSA-N 2-hexadecylicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCC JQJGGMZIMBGQQY-UHFFFAOYSA-N 0.000 description 1
- KMUBFTBPGVULKC-UHFFFAOYSA-N 2-hexyldecyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC KMUBFTBPGVULKC-UHFFFAOYSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- MWKPHOIHTLQZIY-UHFFFAOYSA-N 2-hexyldecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC MWKPHOIHTLQZIY-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- RTXVDAJGIYOHFY-UHFFFAOYSA-N 2-tetradecyloctadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCC RTXVDAJGIYOHFY-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-M 3,3-dimethylbutanoate Chemical compound CC(C)(C)CC([O-])=O MLMQPDHYNJCQAO-UHFFFAOYSA-M 0.000 description 1
- SMKNKOCYSYNJHN-UHFFFAOYSA-N 3-[4-[5-[[3,4-bis(hydroxymethyl)phenyl]methoxy]-2-ethylphenyl]-3-propylphenyl]pentan-3-ol Chemical compound CCCC1=CC(C(O)(CC)CC)=CC=C1C1=CC(OCC=2C=C(CO)C(CO)=CC=2)=CC=C1CC SMKNKOCYSYNJHN-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000640882 Condea Species 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- HLLPKVARTYKIJB-MCQPFKOBSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 HLLPKVARTYKIJB-MCQPFKOBSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960003238 fluprednidene Drugs 0.000 description 1
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- CHCBCLGWJORKKK-UHFFFAOYSA-N hexacosan-12-ol Chemical compound CCCCCCCCCCCCCCC(O)CCCCCCCCCCC CHCBCLGWJORKKK-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- IROBLZDPARQMAB-UHFFFAOYSA-N hexadecan-7-yl octanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)CCCCCCC IROBLZDPARQMAB-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 229940090854 hexyldecyl laurate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ICXHTGWDIYBLCR-UHFFFAOYSA-N tetratriacontan-15-ol Chemical compound CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCCCCCCC ICXHTGWDIYBLCR-UHFFFAOYSA-N 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- Dermatological composition comprising calcitriol lipid vesicles, process for its preparation and its use
- the present invention relates to a pharmaceutical composition, especially dermatological, based on a compound of the family of vitamin D derivatives, and more particularly calcitriol, said vitamin D derivative being present in oily vesicles dispersed in a aqueous phase. It also relates to its preparation process and its use in the preparation of a medicament for the treatment of dermatological conditions, in particular psoriasis.
- Vitamin D derivatives especially calcitriol, are used to regulate calcium levels in the body.
- the use of calcitriol in the treatment of dermatological diseases has in particular been described in US Pat. No. 4,610,978 for the treatment of psoriasis.
- compositions commonly encountered in the prior art contain a high percentage of propenetrating glycol in order to promote the penetration of the active ingredient but are sticky and can cause problems of intolerance (" and patient compliance "Piacquadio & Garlic, Journal of the American Academy of Dermatology, August 1998).
- the problem that the present invention proposes to solve here is therefore to design a physically and chemically stable composition containing at least one vitamin D derivative, preferably calcitriol, for the treatment of psoriasis, the composition according to the invention being also present an ease of use and acceptable cosmetics for application to all areas of the body that may be affected by the pathology.
- the object of the present invention is to provide a hydrophilic formulation based on vitamin D derivative, preferably calcitriol, as an alternative to Silkis® ointment forms.
- This formulation would bring more comfort to the patient and ensure better adherence to treatment.
- vitamin D derivatives and in particular calcitriol are unstable in aqueous media, and sensitive to acidic pH.
- the objective of the present invention is therefore to provide an aqueous composition which makes it possible to overcome a degradation of the vitamin D derivative, preferably calcitriol, while retaining good cosmetic properties. To this end, it seems interesting to work on the structure of the interface between the solubilization medium of the vitamin D derivative, preferably calcitriol, and the aqueous phase.
- CN 1491551 discloses nanocapsule formulations with the active ingredient ivermectin suspended in water produced via polymeric emulsions, i.e. a solvent-free process employing in-situ polymerization of monomer.
- patent FR 2 805 761 discloses lipid nanocapsules containing phosphatidylcholines in combination with a hydrophilic co-surfactant derived from polyethylene glycol, Solutol HS 15.
- a hydrophilic co-surfactant derived from polyethylene glycol, Solutol HS 15.
- co-surfactant is necessary for the production of nanocapsules.
- the method for preparing such nanocapsules is by phase inversion (TIP process), which generates the use of temperature cycles in the process.
- the active ingredients are solubilized in an oil composed of medium chain triglycerides of caprylic and capric acids, marketed under the name Labrafac WL1349 by GATTEFOSSE.
- compositions comprising at least one vitamin D derivative, preferably calcitriol, in solubilized form in a dispersed oily phase make it possible to stabilize this active ingredient and are easy to prepare.
- Such compositions comprise at least one vitamin D derivative, preferably calcitriol, in solubilized form in a hydrophilic environment, do not require the use of polymer or organic solvent, and guarantee the stability of the active ingredient. They can also promote skin penetration of the asset, which is useful in the treatment of dermatological conditions, including psoriasis.
- compositions in particular a pharmaceutical composition, comprising at least one vitamin D derivative, preferably calcitriol, said composition comprising, within a pharmaceutically acceptable vehicle, lipid vesicles consisting of: less a vitamin D derivative;
- lipid vesicles being dispersed in a continuous hydrophilic phase.
- composition according to the invention comprises from 0.00001 to 0.1% of at least one vitamin D derivative by weight relative to the total weight of the composition, preferably from 0.0001 to 0.001%.
- composition according to the invention contains 0.0001% and 0.001% of calcitriol.
- lipid vesicle composition is meant a colloidal lipid system comprising lipid vesicles with solid or semi-solid interface dispersed in a continuous hydrophilic phase, said vesicles containing an oily internal phase in which the vitamin D derivative, from calcitriol is preferably solubilized, and a lamellar coating obtained from at least one non-polymeric surfactant forming the semi-solid or solid interface between the oily internal phase and the continuous hydrophilic phase.
- derivatives of vitamin D is meant calcitriol, calcipotriol, ⁇ 4- [6-Ethyl-4 '- (1-ethyl-1-hydroxy-propyl) -2'-propyl-biphenyl-3-yloxymethyl] 2-hydroxymethyl-phenyl ⁇ -methanol.
- the derivative used is calcitriol.
- composition according to the invention is meant the composition of lipid vesicles, incorporated in a pharmaceutically acceptable vehicle, such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
- a pharmaceutically acceptable vehicle such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
- pharmaceutically acceptable vehicle is meant an excipient or a mixture of excipients component, with the nanoemulsion, the composition according to the invention.
- the present invention relates to compositions comprising vesicles made without organic solvent.
- the composition comprises vesicles and not nanospheres.
- vesicles means particles consisting of a liquid or semi-liquid core (internal phase) at ambient temperature, encapsulated by a solid non-polymeric coating (shell or layer) at room temperature, as opposed to nanospheres which are matrix particles. , ie whose whole mass is solid.
- the nanospheres contain a pharmaceutically acceptable active ingredient, it is finely dispersed in the solid matrix.
- lipid vesicle is understood to mean a vesicle whose heart is composed of one or more liquid or semi-liquid fatty substances at ambient temperature, and whose coating is of a lipophilic and non-polymeric nature. Indeed, the lipid vesicles according to the invention do not require any polymer and therefore no in situ polymerization. In the present application, we speak indifferently of "lipid vesicles” or “vesicles”.
- ambient temperature is meant a temperature of between 15 and 25 ° C.
- the lipid vesicles according to the present invention have an average size of less than 200 nm, preferably less than 150 nm.
- lipid vesicles are present in the composition according to the invention in an amount of between 10 and 30% by weight relative to the total weight of the composition, preferably between 10 and 20%.
- the vesicles each consist of a liquid or semi-liquid core at ambient temperature, coated with a lamellar coating obtained from at least one surfactant.
- the coating (envelope or layer) of surfactant encapsulating the vesicles is preferably composed of a solid material at room temperature. It is not polymeric in nature. Preferably, it has a liquid crystal structure.
- This coating consists of one or more lipophilic surfactants; advantageously, such lipophilic surfactant (s) are chosen from anionic amphiphilic lipids. More preferably, the surfactant (s) are chosen from the family of phospholipids, preferably from the family of lecithins, and preferably the lipophilic surfactant is a hydrogenated lecithin, advantageously including the percentage of saturated phosphatidylcholine (or hydrogenated) is high. High percentage means a quantity of 70 to 99% of saturated phosphatidylcholine (or hydrogenated) relative to the total weight of lecithin. Phosphatidylcholines show good compatibility with the skin with a very low irritating potential.
- the lecithin used in the present invention being solid at room temperature, this promotes the formation of a semi-solid interface in the composition.
- lecithins As usable lecithins, mention may be made in particular of natural or synthetic soy or egg lecithins having a content of hydrogenated phosphatidylcholine greater than 70%, for example LIPOID of grade S75-3, S100-3 or SPC-3. Epikuron grade 200 SH or 10OH, or Phospholipon grade 8OH, 9OH or 10OH.
- the coating of lipophilic surfactant enveloping the liquid or semi-liquid core as defined above is present in an amount of between 0.1 and 10% by weight, preferably between 1 and 5% by weight relative to the total weight of the composition. .
- the coating of lipophilic surfactant, in particular lecithin, according to the invention alone allows the encapsulation of the vitamin D derivative, in particular calcitriol, which avoids the contact of this active agent with the hydrophilic phase, and thus provides it with the chemical stability.
- the composition, and in particular the coating is substantially free of co-surfactant distinct from the anionic amphiphilic lipids, thus substantially free of co-surfactant distinct from the phospholipids, and in particular substantially free of hydrophilic co-surfactant.
- the composition does not contain any co-surfactant other than ionic amphiphilic lipids.
- the vitamin D derivative especially calcitriol, is thus solubilized in the heart of the vesicles.
- Said core, or oily internal phase comprises at least one liquid or semi-liquid fatty substance at ambient temperature.
- composition of the internal phase is therefore essential for the stability of the active ingredient.
- oily internal phase must of course be compatible with the asset to be solubilized.
- This oily internal phase comprises at least one oily solvent, chosen from tocopherol esters, and triglycerides and oils containing them.
- the oily solvent is selected from vitamin E acetate and caprylic / capric acid triglycerides, such as Miglyol 812.
- the internal phase may also comprise one or more non-solubilizing liquid or semi-liquid at room temperature fatty substances of the active ingredient, such as: 2-alkyl alkanols and their esters, such as: butyloctanol, hexyldecanol, octyldecanol, isostearyl alcohol, octyldodecanol, decyltetradecanol, undecylpentadecanol, dodecylhexadecanol, tetradecyloctadecanol, hexyldecyloctadecanol, tetradecylicosanol, cetylarachidol and the mixture of iso-cetyl alcohol, iso-stearyl alcohol, iso-arachidyl alcohol.
- 2-alkyl alkanols and their esters such as: butyloctanol, hexyldecanol, o
- esters of said alcohols mention may be made of: octyldodecyl octanoate; hexyldecyl caprylate; hexyldecyl laurate; hexyldecyl palmitate; hexyldecyl stearate; and octyldodecyl meadowfoamate, which is an ester of octyldodecanol and fatty acids derived from meadowfoam seed oil Alba;
- esters of fatty acids or of fatty alcohols such as isopropyl palmitate, isostearyl neopentanoate and octyl palmitate;
- N-acetylated amino acid esters and fatty alcohol such as N-lauroyl isopropyl sarcosinate
- non-solubilizing fatty substance of the active is meant a compound for which the vitamin D derivative has a solubility of less than or equal to 1%.
- Such a fatty substance is present in an amount of between 90 and 99.99% by weight relative to the total weight of the internal phase; and in an amount of between 1 and 25% by weight relative to the total weight of the composition, preferably between 5 and 15%.
- the continuous hydrophilic phase comprises water.
- This water may be demineralized water, floral water such as blueberry water, or natural thermal or mineral water, for example chosen from Vittel water, Vichy basin water Uriage, the water of the Roche Posay, the water of the Bourboule, the water of Enghien-les-Bains, the water of Saint Gervais-les-Bains, the water of Néris-les-Bains, the water of Allevard-les-Bains, the water of Digne, the water of Maiz restaurants, the water of Neyrac-les-Bains, the water of Lons-le-Saunier, the Good Waters, the water Rochefort, the water of Saint Christau, the water of the Fumades and the water of Tercis-les-bains, the water of Avène or the water of Aix les Bains.
- the water may be present at a content of between 70 and 90% by weight relative to the total weight of the composition, preferably between 80 and 90% by weight.
- the hydrophilic phase may also comprise other hydrophilic compounds such as preservatives or humectants.
- preservatives such as parabens or phenoxyethanol.
- humectants such as glycerine.
- the hydrophilic phase may also comprise active principles not sensitive to the presence of water, these active ingredients being useful in the treatment of dermatological pathologies.
- the corticosteroid is selected from the group consisting of betamethasone, clobetasol, clobetasone, deoximethasone, diflucortolon, diflorasone, fluocinonide, flumethasone, fluocinolon, fluticasone, fluprednidene, halcinonide, hydrocortisone, momethasone, triamcinolon and their pharmaceutically acceptable esters and acetonides and mixtures thereof.
- esters or acetonides mention may be made of those selected from the group consisting of 17-valerate, 17-propionate, 17,21-dipropionate, acetonide, acetonide-21 -N benzoyl-2-methyl- ⁇ -alaninate, acetonide-21- (3,3-dimethylbutyrate) and 17-butyrate.
- the hydrophilic phase may comprise clobetasol 17-propionate (or "clobetasol propionate").
- the amount of corticosteroid in solubilized form in the hydrophilic phase of the composition of the invention is from 0.00005 to 3% by weight relative to the total weight of the composition, preferably from 0.0001 to 1% by weight. and more particularly from 0.001 to 0.1% by weight.
- the corticosteroids present in the composition as described above may be present within the oily vesicles according to the present invention. In this case, they end up in the oily inner phase which includes the solubilized vitamin D derivative.
- the gelling agent may also be chosen from natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, sodium alginate, pectin, dextrin, chitosan, alone or as a mixture.
- natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, sodium alginate, pectin, dextrin, chitosan, alone or as a mixture.
- the gelling agent is used in particular at a concentration of between 0.1 and 10% by weight, preferably between 0.1 and 2% by weight.
- the lipid vesicle composition as described above is incorporated in a pharmaceutically acceptable vehicle, such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
- a pharmaceutically acceptable vehicle such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
- pharmaceutically acceptable vehicle is meant an excipient or a mixture of component excipients, the composition according to the invention.
- composition in particular a pharmaceutical composition, said composition comprising the nanoemulsion containing the lipid nano-vesicles defined above in the text of the present invention in a pharmaceutically acceptable vehicle, such as a gel, a gel, cream or emulsion as a cream or lotion.
- a pharmaceutically acceptable vehicle such as a gel, a gel, cream or emulsion as a cream or lotion.
- the nanoemulsion is dispersed in a hydrophilic phase which comprises at least one gelling agent.
- This gelling agent is preferably a cellulose derivative chosen from semi-synthetic cellulosic gelling agents, such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, and hydroxypropylcellulose, taken alone or in mixture. Hydroxypropylmethylcellulose or hydroxyethylcellulose is preferably used.
- the gelling agent may also be chosen from natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, biopolymers such as sodium alginate, pectin, dextrin, chitosan, sodium hyaluronate and their derivatives alone or as a mixture, the agent gelling agent may also be chosen from Sepigel 305 compound consisting of a polyacrylamide / isoparaffin C13-C14 / laureth-7 mixture, or Simulgel 600PHA, namely sodium acryloyld
- the gelling agent is used in particular at a concentration of between 0.1 and 10% by weight, preferably between 0.1 and 2% by weight relative to the total weight of the composition.
- the pharmaceutically acceptable vehicle is a gel-cream
- the nanoemulsion is dispersed in a vehicle composed of a hydrophilic phase and a fatty phase,
- the nanoemulsion is dispersed in a vehicle composed of a hydrophilic phase, a fatty phase, and at least one surfactant or emulsifier.
- the composition according to the invention therefore comprises a fatty phase.
- This fatty phase may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.
- mineral oil there may be mentioned, for example, paraffin oils of different viscosities such as Primol 352®, Marcol 82®, Marcol 152® sold by the company Esso.
- sweet almond oil there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.
- an ester such as cetearyl isononanoate, such as the product sold under the name Cetiol SN PH® by Cognis France, and isopropyl palmitate, as the product sold under the name Crodamol IPP® by the company Croda company, diisopropyl adipate sold under the name Crodamol DA by the company Croda, caprylic / capric triglyceride such as Miglyol 812® sold by the company HuIs / Univar.
- volatile or non-volatile silicone oil mention may be made of dimethicones, such as the products sold under the name Q7-9120® silicone fluid with a viscosity of 20 to 12500 is, or the product sold under the name ST-Cyclomethicone-5 NF® by the Dow corning company.
- solid fatty substances such as natural or synthetic waxes, fatty acids such as stearic acid, fatty alcohols such as Speziol C18 pharma sold by Cognis, and tribehenate type texturing agents, such as Compritol 888 sold by Gattefossé or hydrogenated castor oils such as Cutina HR sold by Cognis. In this case, those skilled in the art will adapt the heating temperature of the preparation depending on the presence or absence of these solids.
- the emulsion when the vehicle of the composition according to the invention is an emulsion, the emulsion is in the form of an oil-in-water (O / W) emulsion.
- the emulsion therefore comprises at least one emulsifier.
- the preferred concentrations of emulsifiers are between 0.001 and 20% by weight relative to the total weight of the composition. More preferably the concentration is between 1 and 15% and preferably between 3 and 1 1% by weight relative to the total weight of the composition.
- the emulsifying power of emulsifiers is closely related to the polarity of the molecule. This polarity is defined by the HLB (Hydrophile / Lipophilic Balance).
- High HLB indicates that the hydrophilic moiety is predominant, and conversely, low HLB indicates that the lipophilic moiety is predominant.
- HLB values greater than about 10 correspond to hydrophilic surfactants.
- Emulsifiers can be classified, according to their structure, under the generic terms "ionic” (anionic, cationic, amphoteric) or "nonionic".
- Nonionic emulsifiers are emulsifiers that do not dissociate into ions in water and are therefore insensitive to pH changes.
- Nonionic emulsifiers are particularly well suited for the preparation of oil-in-water type emulsions, object of the present invention.
- the emulsifying system, component of the emulsion of the invention comprises at least one non-ionic emulsifier with predominantly hydrophilic fraction, that is to say having a high HLB greater than about 10.
- said nonionic emulsifiers having low HLB have an HLB of less than 10.
- the nonionic emulsifiers can be used alone or in a mixture of two or more of them to form the emulsifying system comprising the emulsion of the invention.
- one or more pairs of "nonionic emulsifier of high HLB” / "nonionic emulsifier of low HLB” will be used as an emulsifying system, it may in particular be a nonionic emulsifying system comprising at least a nonionic emulsifier having an HLB greater than about 10 and at least one nonionic surfactant having an HLB of less than about 10.
- the ratio of each of the two emulsifiers forming the abovementioned pair is most often determined by the calculation of the required HLB of the fat phase used.
- hydrophilic emulsifiers of the type, Glycery! Stearate & PEG-100 Stearate sold under the name Arlacel 165FL® by Uniqema; PEG 6 stearate and PEG 32 stearate sold under the name TEFOSE 1500® by Gattefossé, PEG 20 methyl glucose sesquistearate sold under the name Glucamate SSE 20® by Amerchol, Poiyoxyethyiene (21) Stéasy!
- the emulsifiers are amphiphilic compounds which have a hydrophobic part having an affinity for the oil and a hydrophilic part having an affinity for water thus creating a link between the two phases. Ionic or nonionic emulsifiers thus stabilize O / W emulsions by adsorbing at the interface and forming lamellar layers of liquid crystals.
- the oil-in-water emulsion according to the invention also comprises a hydrophilic phase or an aqueous phase.
- hydrophilic phase which constitutes the pharmaceutically acceptable vehicle, alone or within an emulsion, is meant any hydrophilic phase as defined previously in the present invention.
- composition according to the invention may also contain, within the nanoemulsion or the pharmaceutically acceptable vehicle, additives or combinations of additives, such as: preserving agents;
- UV-A and UV-B filters are UV-A and UV-B filters
- glycols for example propylene glycol, glycol ethers, N-methyl-2-pyrrolidone or else dimethylsulfoxide.
- additives may be present in the composition from 0 to 20% by weight relative to the total weight of the composition.
- the usable pharmaceutical composition consisting of the composition of lipid vesicles in a pharmaceutically acceptable vehicle according to the invention is intended for the treatment of the skin and may be administered topically, parenterally or orally. Preferably, the composition is administered topically. Topically, we mean an application on the skin or the mucous membranes.
- the pharmaceutical composition may be in liquid or pasty form, and more particularly in the form of capsules, dragees, or syrups.
- composition may be in the form of suspensions for infusion or for injection.
- the composition may be in liquid or pasty form, and more particularly in the form of creams, milks, ointments, soaked swabs, syndets, wipes, gels, sprays, foams, lotions, sticks, shampoos, or washing bases.
- composition according to the invention comprises, in a pharmaceutically acceptable vehicle, by weight relative to the total weight of the composition: a) 0.1 to 5% of surfactant chosen from anionic amphiphilic lipids, preferably lecithin; b) 1 to 50% of liquid or semi-liquid fat at room temperature, preferably tocopherol esters such as vitamin E acetate or triglycerides of caprylic / capric acids; preferably from 10 to 25% c) between 0.00001 and 0.1% of at least one derivative of vitamin D, preferably calcitriol; d) 0 to 2% gelling agent, preferably a cellulose derivative.
- surfactant chosen from anionic amphiphilic lipids, preferably lecithin
- tocopherol esters such as vitamin E acetate or triglycerides of caprylic / capric acids
- d) 0 to 2% gelling agent preferably a cellulose derivative.
- the invention also relates to a process for preparing compositions comprising at least one derivative of vitamin D, preferably calcitriol.
- This process uses a High Pressure Homogenizer (HHP).
- HHP High Pressure Homogenizer
- the method according to the invention does not use a Phase Inversion Temperature (TIP) (used in particular in patents FR 2 805 761 and FR 2 840 531), and therefore does not require a cycle (s). rise and fall in temperature.
- TIP Phase Inversion Temperature
- the process according to the invention is carried out in cold HHP; HHP therefore does not require successive heating and cooling, and is not thermoregulated.
- the method implemented in the present invention comprises the following steps:
- calcitriol is solubilized in the fatty substance, for example vitamin E acetate or triglycerides of caprylic / capric acids.
- the lipophilic surfactant in particular lecithin, for example, Phospholipon 9OH or Lipoid S75-3 is dispersed in the oily phase.
- the two phases are preferably separately heated to a temperature preferably greater than 50 ° C.
- the lipophilic phase is heated to about 60 ° C to facilitate dispersion of the surfactant (step (Ni)).
- the lipophilic phase is allowed to cool before the incorporation of the vitamin D derivative solution (step (i)), in order to avoid any degradation thereof related to the temperature of implementation of the vesicles.
- step (iv) Mixing of the oily and hydrophilic phases obtained at the end of step (iii). Once the two phases in temperature, about 50 ° C, they are mixed with stirring. Once this pre-homogenization has been carried out, the emulsion is introduced into the High Pressure Homogenizer (HHP).
- HHP High Pressure Homogenizer
- the composition is not heated, the HHP system is not controlled temperature.
- the step of gelation of the composition takes place at the end of manufacture after the various passages in the HHP, during the cooling of the composition.
- the gelling agent is then added with sufficient stirring to a homogeneous dispersion, during the cooling of the composition. Stirring is maintained for the time necessary to complete the gelation step of the system.
- the gel-cream or the emulsion is carried out beforehand. Then the lipid vesicle composition is incorporated into the finalized vehicle.
- the process may be adapted by those skilled in the art depending on the different ingredients used to maintain the stability of the lipid vesicles within the final composition.
- composition according to the invention can be used as a medicament.
- the subject of the invention is also the use of the composition according to the invention for the preparation of a medicament intended to treat dermatological affections, in particular human affections.
- the use of the composition according to the invention is more particularly intended for the treatment of psoriasis.
- the composition according to the invention is indeed suitable for use in the treatment of dermatological conditions, especially human, and preferably for the treatment of psoriasis.
- compositions comprising a vitamin D derivative, and especially calcitriol, will now be given.
- Example 1 Preformulation Study of Calcitriol Preliminary preformulation studies were conducted to guide the choice of lipid core (oily internal phase) of our lipid vesicles.
- the graphs below present the results of tests of stability and solubility of calcitriol in two excipients: These studies of solubility and stability of calcitriol aim at finding the oil which will allow a good solubility of calcitriol for the proposals of phase used in this concept and good stability of calcitriol in this excipient.
- Calcitriol is stable for 1 month at 800 ppm at all three temperatures (4 ° C, Tamb and 40 9 C) in Miglyol 812 (caprylic / capric triglyceride: MTC) and tocopherol acetate.
- the method implemented in this invention utilizes a High Pressure Homogenizer (HHP).
- HHP High Pressure Homogenizer
- the hydrogenated phosphatidylcholine used is dispersed in the oily phase as a function of the phosphatidylcholine content.
- the oily phase is heated to about 75 ° C to ensure the dispersion of phosphatidylcholine in this phase.
- the temperature of this phase must be about 50 ° C, in order to avoid a degradation of the calcitriol linked to the temperature of implementation of lipid vesicles.
- the hydrophilic phase is heated to about 50 ° C.
- the two phases in temperature are mixed with stirring (turrax homogenization for 2 minutes at 8000 rpm). Once this pre-homogenization has been carried out, the emulsion is introduced into the HHP.
- the use of a high pressure homogenizer requires setting the number of passages in the homogenization chamber and the homogenization pressure.
- the Homogenization process is then applied: minimum 500 bar up to 1000 bar of homogenization pressure in the homogenization chamber, between 5 and 10 passages in the homogenization chamber.
- the nanoemulsion is not heated, the HHP system is not controlled temperature.
- the step of gelation of the composition occurs at the end of manufacture after the various passages in the HHP, during the cooling of the composition .
- the gelling agent is then added with sufficient stirring to a homogeneous dispersion, during the cooling of the composition, or the gelling agent is hydrated in a part of water of our system and then diluted at the end of manufacture.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0756165A FR2917976B1 (fr) | 2007-06-29 | 2007-06-29 | Composition dermatologique comprenant des vehicules lipidiques de calcitriol, son procede de preparation et son utilisation |
PCT/FR2008/051193 WO2009007622A2 (fr) | 2007-06-29 | 2008-06-27 | Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2173326A2 true EP2173326A2 (fr) | 2010-04-14 |
Family
ID=38957738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08806120A Withdrawn EP2173326A2 (fr) | 2007-06-29 | 2008-06-27 | Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100221350A1 (fr) |
EP (1) | EP2173326A2 (fr) |
CA (1) | CA2691398A1 (fr) |
FR (1) | FR2917976B1 (fr) |
WO (1) | WO2009007622A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2942050T3 (da) * | 2014-05-06 | 2022-11-21 | S I I T S R L Servizio Int Imballaggi Termosaldanti | Spraybar, olieholdig sammensætning baseret på fedtopløselige vitaminer fra gruppe d og anvendelse deraf |
FR3041541B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee comprenant de l'ivermectine |
CN112630257B (zh) * | 2020-12-28 | 2024-03-22 | 宁波铭瑞中兴电子科技有限公司 | 一种玻璃水水箱监控方法、系统、智能终端以及存储介质 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023271A (en) * | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
FR2735658B1 (fr) * | 1995-06-21 | 1997-09-12 | Capsulis | Encapsulation de composes a usage alimentaire par des tensioactifs |
FR2709666B1 (fr) * | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
FI100692B (fi) * | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
AU2588297A (en) * | 1996-04-04 | 1997-10-29 | Ortho Pharmaceutical Corporation | Liposome-based topical vitamin d formulation |
GB9906009D0 (en) * | 1999-03-16 | 1999-05-12 | Nycomed Pharma As | Product |
FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
ES2259034T3 (es) * | 2000-06-06 | 2006-09-16 | Basf Aktiengesellschaft | Uso de un enantiomero del acido lipoico en cosmeticos y dermatologicos. |
FR2871698B1 (fr) * | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse |
-
2007
- 2007-06-29 FR FR0756165A patent/FR2917976B1/fr not_active Expired - Fee Related
-
2008
- 2008-06-27 CA CA002691398A patent/CA2691398A1/fr not_active Abandoned
- 2008-06-27 EP EP08806120A patent/EP2173326A2/fr not_active Withdrawn
- 2008-06-27 WO PCT/FR2008/051193 patent/WO2009007622A2/fr active Application Filing
-
2009
- 2009-12-24 US US12/647,021 patent/US20100221350A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2009007622A2 * |
Also Published As
Publication number | Publication date |
---|---|
FR2917976B1 (fr) | 2010-05-28 |
US20100221350A1 (en) | 2010-09-02 |
FR2917976A1 (fr) | 2009-01-02 |
CA2691398A1 (fr) | 2009-01-15 |
WO2009007622A2 (fr) | 2009-01-15 |
WO2009007622A3 (fr) | 2009-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2854793B1 (fr) | Nanocapsules lipidiques comprenant un rétinoide, nanodispersion et composition les contenant, leur procédé de préparation et leur utilisation en dermatologie | |
EP2224908B1 (fr) | Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene. | |
EP2125117B1 (fr) | Emulsion comprenant au moins un retinoide et du péroxyde de benzoyle | |
WO2007020349A1 (fr) | Émulsion de type huile-dans-eau pour application topique en dermatologie | |
EP2388009B1 (fr) | Composition dermatologique comprenant des nanocapsules d'avermectine, son procédé de préparation et son utilisation | |
EP1758588B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
EP3076944A1 (fr) | Microcapsules lipidiques comprenant de preference un actif lipophile et composition les contenant, leur procede de preparation et leur utilisation en dermatologie et en cosmetique | |
EP2097077A1 (fr) | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoïque et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations | |
EP2240152B1 (fr) | Composition comprenant un retinoide et du peroxyde de benzoyle disperse | |
Tungadi et al. | Transdermal delivery of snakehead fish (Ophiocephalus striatus) nanoemulgel containing hydrophobic powder for burn wound | |
EP2872116B1 (fr) | Composition dermatologique comprenant des oléosomes et des rétinoïdes, son procédé de préparation et son utilisation | |
EP2173326A2 (fr) | Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation | |
EP2029133B1 (fr) | Compositions comprenant au moins un dérivé de l'acide naphtoïque et au moins un agent filmogène, leurs procédés de préparation, et leurs utilisations | |
EP3302421B1 (fr) | Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques | |
FR2924943A1 (fr) | Composition dermatologique comprenant des nanocapsules polymeriques de calcitriol, son procede de preparation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100129 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20120223 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130208 |